SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes. d. 2026;4(19):38-39. Accessed September 17, 2026. https://www.thediabzen.com/index.php/d/article/view/62